https://hemogenyx.com/announcements/hemogenyx-pharma-plc-total-voting-rights/2019-12-08T13:13:10+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-cdx-patent-application/2019-12-08T13:13:06+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-director-pdmr-shareholding/2019-12-08T13:13:02+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-result-of-agm/2019-12-08T13:12:59+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-development-of-apbhc/2019-12-08T13:12:54+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-cdx-antibody-is-effective-against-aml-in-vivo/2019-12-08T13:12:48+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-second-price-monitoring-extn/2019-12-08T13:12:35+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-price-monitoring-extension/2019-12-08T13:12:42+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-posting-of-annual-report-and-notice-of-agm/2019-12-08T13:12:29+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-variation-of-terms-of-warrant-instrument/2019-12-08T13:12:25+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-director-pdmr-shareholding-2/2019-12-08T13:10:30+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-final-results-for-the-year-ended-31-december-2018/2019-12-08T13:12:12+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-presentation-at-cancer-immunotherapy-conference/2019-12-08T13:12:08+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-operations-update/2019-12-08T13:12:02+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-directorate-change/2019-12-08T13:11:57+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-directorate-change-appointment/2019-12-08T13:11:53+00:00https://hemogenyx.com/announcements/162/2019-12-08T13:11:49+00:00https://hemogenyx.com/announcements/164/2019-12-08T13:11:43+00:00https://hemogenyx.com/announcements/166/2019-12-08T13:11:36+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-half-year-report/2019-12-08T13:11:26+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-change-of-adviser/2019-12-08T13:11:31+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-hemogenyx-to-present-at-oxford-conference/2019-12-08T13:11:22+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-result-of-agm-2/2019-12-08T13:11:17+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-investor-presentation/2019-12-08T13:11:12+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-posting-of-annual-report-notice-of-agm/2019-12-08T13:11:07+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-development-agreement/2019-12-08T13:11:02+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-research-collaboration-with-rockefeller-university/2019-12-08T13:10:55+00:00https://hemogenyx.com/announcements/Final-Results-for-the-year-ended-31-December-2017/2019-09-19T14:03:53+01:00https://hemogenyx.com/announcements/Director-PDMR-Shareholding/2019-09-19T14:06:50+01:00https://hemogenyx.com/announcements/Directorate-Change/2019-09-23T07:04:18+01:00https://hemogenyx.com/announcements/Collaboration-with-major-US-biotechnology-company/2019-09-23T07:05:32+01:00https://hemogenyx.com/announcements/Advisory-Board-Appointment/2019-09-23T07:05:49+01:00https://hemogenyx.com/announcements/Align-Research-Initiation-of-Coverage/2019-09-19T14:26:54+01:00https://hemogenyx.com/announcements/Statement-re.-Share-Price-Movement-Lead-candidate-shown-to-be-effective-in-treatment-of-Leukemia/2019-09-19T14:30:49+01:00https://hemogenyx.com/announcements/director-pdmr-shareholding-2/2019-09-30T17:31:23+01:00https://hemogenyx.com/announcements/Director-PDMR-Shareholding-3/2019-09-19T14:38:27+01:00https://hemogenyx.com/announcements/Hemogenyx-Welcomes-N.Y.-Lt.-Governor-to-its-Labs/2019-09-19T14:41:32+01:00https://hemogenyx.com/announcements/AGM-Statement/2019-09-24T11:29:00+01:00https://hemogenyx.com/announcements/Result-of-AGM/2019-09-19T14:48:50+01:00https://hemogenyx.com/announcements/University-of-Oxford-Collaboration/2019-09-23T07:06:22+01:00https://hemogenyx.com/announcements/Directorate-Change-2/2019-09-23T07:09:28+01:00https://hemogenyx.com/announcements/Notice-of-AGM/2019-09-23T07:12:36+01:00https://hemogenyx.com/announcements/Statement-re.-media-comment/2019-09-23T07:17:18+01:00https://hemogenyx.com/announcements/Statement-re-Press-Comment/2019-09-23T07:17:04+01:00https://hemogenyx.com/announcements/Price-Monitoring-Extension/2019-09-23T07:16:51+01:00https://hemogenyx.com/announcements/Second-Price-Monitoring-Extn/2019-09-23T07:16:39+01:00https://hemogenyx.com/announcements/Second-Price-Monitoring-Extn-2/2019-09-23T07:16:28+01:00https://hemogenyx.com/announcements/Price-Monitoring-Extension-2/2019-09-23T07:15:59+01:00https://hemogenyx.com/announcements/Second-Price-Monitoring-Extn-3/2019-09-23T07:15:41+01:00https://hemogenyx.com/announcements/Second-Price-Monitoring-Extension/2019-09-23T07:15:24+01:00https://hemogenyx.com/announcements/LakePharma-appointed-for-lead-product-development/2019-09-23T07:17:50+01:00https://hemogenyx.com/announcements/Director-PDMR-Shareholding-4/2019-09-23T07:38:43+01:00https://hemogenyx.com/announcements/Director-PDMR-Shareholding-5/2019-09-23T07:38:52+01:00https://hemogenyx.com/announcements/Cornell-University-update/2019-09-23T07:39:01+01:00https://hemogenyx.com/announcements/Admission-and-First-Day-of-Dealings/2019-09-23T07:39:19+01:00https://hemogenyx.com/announcements/Result-of-General-Meeting-Silver-Falcon-Plc/2019-09-20T08:34:59+01:00https://hemogenyx.com/announcements/Investor-presentations-Silver-Falcon-Plc/2019-09-23T07:39:28+01:00https://hemogenyx.com/announcements/Half-year-Report-Silver-Falcon-Plc/2019-09-23T07:39:37+01:00https://hemogenyx.com/announcements/Proposed-acquisition-and-Placing-Subscription-Silver-Falcon-Plc/2019-09-23T07:39:45+01:00https://hemogenyx.com/announcements/Final-Results-Silver-Falcon-Plc/2019-09-23T07:41:30+01:00https://hemogenyx.com/announcements/Proposed-acquisition-of-Lime-Holdings-Limited-pdf-Silver-Falcon-Plc/2019-09-23T07:22:02+01:00https://hemogenyx.com/announcements/Interim-Report-for-the-period-ended-30-June-2016-pdf-Silver-Falcon-Plc/2019-09-23T07:22:55+01:00https://hemogenyx.com/announcements/Results-of-Annual-General-Meeting-pdf-Silver-Falcon-Plc/2019-09-23T07:23:54+01:00https://hemogenyx.com/announcements/Posting-of-Annual-Report-Accounts-pdf-Silver-Falcon-Plc/2019-09-20T11:18:20+01:00https://hemogenyx.com/announcements/Final-Results-for-period-ended-31-December-2015-pdf-Silver-Falcon-Plc/2019-09-23T07:24:59+01:00https://hemogenyx.com/announcements/Change-of-Accounting-Reference-Date-pdf-Silver-Falcon-Plc/2019-09-23T07:25:29+01:00https://hemogenyx.com/announcements/Statement-re-possible-acquisition-pdf-Silver-Falcon-Plc/2019-09-23T07:26:35+01:00https://hemogenyx.com/announcements/Suspension-of-trading-pdf-Silver-Falcon-Plc/2019-09-23T07:27:03+01:00https://hemogenyx.com/announcements/Suspension-pdf-Silver-Falcon-Plc/2019-09-23T07:26:47+01:00https://hemogenyx.com/announcements/Appointment-of-Financial-Advisor-pdf-Silver-Falcon-Plc/2019-09-23T07:27:16+01:00https://hemogenyx.com/announcements/Statement-re-media-speculation-pdf-Silver-Falcon-Plc/2019-09-23T07:27:27+01:00https://hemogenyx.com/announcements/Interim-Report-for-the-period-ended-31-August-2015-pdf-Silver-Falcon-Plc-opens-in-a-new-window/2019-09-23T15:36:39+01:00https://hemogenyx.com/announcements/Holding-s-in-Company-pdf-Silver-Falcon-Plc/2019-09-23T07:29:46+01:00https://hemogenyx.com/announcements/Holding-s-in-Company-pdf-Silver-Falcon-Plc-2/2019-09-23T07:29:56+01:00https://hemogenyx.com/announcements/Appointment-of-Broker-pdf-Silver-Falcon-Plc/2019-09-23T07:30:06+01:00https://hemogenyx.com/announcements/Holding-s-in-Company-pdf-Silver-Falcon-Plc-3/2019-09-23T07:30:37+01:00https://hemogenyx.com/announcements/Holding-s-in-Company-pdf-Silver-Falcon-Plc-4/2019-09-23T07:30:54+01:00https://hemogenyx.com/announcements/Placing-of-Shares-admission-to-Official-List-LSE-pdf-Silver-Falcon-Plc/2019-09-23T07:31:04+01:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-hemogenyx-scientific-advisor-receives-lasker-award/2019-12-08T13:13:15+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-half-year-report-2/2019-12-08T13:13:20+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-presentation-at-ny-stem-cell-foundation-conference/2019-12-08T13:13:25+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-presentation-at-the-investival-showcase/2019-12-08T13:25:02+00:00https://hemogenyx.com/announcements/hemogenyx-pharma-plc-presentation-at-the-ny-oncology-investor-conf/2019-12-08T13:16:34+00:00https://hemogenyx.com/announcements/research-agreement-with-global-pharma-company/2019-12-08T13:08:39+00:00https://hemogenyx.com/announcements/operational-update/2019-12-08T13:35:48+00:00https://hemogenyx.com/announcements/car-t-cells-are-effective-against-aml-in-vitro/2020-01-15T13:02:56+00:00https://hemogenyx.com/announcements/placing-and-subscription-to-raise-approximately-650-000/2020-01-30T14:05:49+00:00https://hemogenyx.com/announcements/director-pdmr-shareholding-6/2020-06-29T15:57:53+01:00https://hemogenyx.com/announcements/approval-and-issuance-of-u-s-hu-phec-patent/2020-02-10T17:22:43+00:00https://hemogenyx.com/announcements/car-t-cells-are-effective-against-aml-in-vivo/2020-02-19T20:35:52+00:00https://hemogenyx.com/announcements/total-voting-rights/2020-02-26T17:21:25+00:00https://hemogenyx.com/announcements/approval-and-issuance-of-european-hu-phec-patent/2020-04-21T14:28:22+01:00https://hemogenyx.com/announcements/covid-19-project-initiated/2020-04-22T11:15:36+01:00https://hemogenyx.com/announcements/final-results-for-the-year-ended-31-december-2019/2020-04-30T18:36:34+01:00https://hemogenyx.com/announcements/tr-1-standard-form-for-notification-of-major-holdings/2020-05-03T20:56:33+01:00https://hemogenyx.com/announcements/tr-1-standard-form-for-notification-of-major-holdings-2/2020-05-03T21:00:09+01:00https://hemogenyx.com/announcements/tr-1-standard-form-for-notification-of-major-holdings-3/2020-05-07T14:07:32+01:00https://hemogenyx.com/announcements/conditional-placing-to-raise-2-500-000/2020-05-13T03:42:37+01:00https://hemogenyx.com/announcements/posting-of-annual-report-notice-of-annual-general-meeting/2020-05-13T09:46:37+01:00https://hemogenyx.com/announcements/warrant-exercise/2020-05-18T11:34:05+01:00https://hemogenyx.com/announcements/total-voting-rights-2/2020-05-29T11:17:08+01:00https://hemogenyx.com/announcements/tr-1-standard-form-for-notification-of-major-holdings-4/2020-05-27T14:35:05+01:00https://hemogenyx.com/announcements/cdx-development-agreement-extension/2020-06-02T11:57:45+01:00https://hemogenyx.com/announcements/result-of-annual-general-meeting-and-completion-of-placing/2020-06-04T15:42:09+01:00https://hemogenyx.com/announcements/covid-19-project-update/2020-06-15T00:05:32+01:00https://hemogenyx.com/announcements/agreement-for-the-development-of-new-treatments-for-autoimmune-diseases/2020-06-25T17:19:01+01:00https://hemogenyx.com/announcements/hemogenyx-chairman-receives-tang-prize/2020-06-23T20:52:39+01:00https://hemogenyx.com/announcements/director-pdmr-shareholding-7/2020-06-30T10:34:08+01:00https://hemogenyx.com/announcements/total-voting-rights-3/2020-07-01T13:55:13+01:00https://hemogenyx.com/announcements/new-corporate-video-and-investor-webinar/2020-07-05T12:40:49+01:00https://hemogenyx.com/announcements/u-s-subsidiary-change-of-name/2020-07-10T13:01:21+01:00https://hemogenyx.com/announcements/grant-of-options/2020-07-13T15:34:30+01:00https://hemogenyx.com/announcements/further-re-development-agreement/2020-07-13T15:29:28+01:00https://hemogenyx.com/announcements/broker-s-research-note/2020-07-29T10:57:42+01:00https://hemogenyx.com/announcements/car-t-agreement-with-university-of-pennsylvania/2020-08-11T07:23:45+01:00https://hemogenyx.com/announcements/presentations-at-cancer-immunotherapy-symposia/2020-08-13T18:41:03+01:00https://hemogenyx.com/announcements/grant-of-options-2/2020-08-21T09:54:54+01:00https://hemogenyx.com/announcements/further-re-grant-of-options/2020-09-22T12:53:37+01:00https://hemogenyx.com/announcements/half-year-report-interim-results-for-the-period-ended-30-june-2020/2020-09-29T21:48:45+01:00https://hemogenyx.com/announcements/car-t-cells-with-a-safety-switch-are-effective-against-aml-in-vitro/2020-10-05T18:24:25+01:00https://hemogenyx.com/announcements/presentation-at-the-american-society-of-hematology-meeting/2020-10-16T19:06:30+01:00https://hemogenyx.com/announcements/cdx-development-agreement-further-extension/2020-10-26T23:02:23+00:00https://hemogenyx.com/announcements/financing-facility-of-up-to-60-million/2020-11-18T10:54:23+00:00https://hemogenyx.com/announcements/posting-of-circular/2020-12-01T21:51:28+00:00https://hemogenyx.com/announcements/1162/2020-12-08T09:47:27+00:00https://hemogenyx.com/announcements/result-of-general-meeting/2021-01-06T16:41:15+00:00https://hemogenyx.com/announcements/car-t-master-translational-agreement-with-penn/2021-01-05T09:37:22+00:00https://hemogenyx.com/announcements/update-on-cdx-antibody-development/2021-01-13T02:25:40+00:00https://hemogenyx.com/announcements/publication-of-prospectus/2021-01-29T14:28:09+00:00https://hemogenyx.com/announcements/draw-down-under-financing-facility-agreement/2021-02-03T11:42:49+00:00https://hemogenyx.com/announcements/allotment-of-shares/2021-02-09T22:55:42+00:00https://hemogenyx.com/announcements/conversion-of-convertible-loan-notes/2021-02-26T05:18:26+00:00https://hemogenyx.com/announcements/1203/2021-02-26T11:40:37+00:00https://hemogenyx.com/announcements/hemo-car-t-update/2021-03-02T20:43:13+00:00https://hemogenyx.com/announcements/h-c-wainwright-investment-conference/2021-03-07T17:45:09+00:00https://hemogenyx.com/announcements/director-pdmr-shareholding-8/2021-03-08T22:18:47+00:00https://hemogenyx.com/announcements/conversion-of-convertible-loan-notes-2/2021-03-26T10:41:13+00:00https://hemogenyx.com/announcements/allotment-of-shares-2/2021-03-27T14:50:55+00:00https://hemogenyx.com/announcements/total-voting-rights-4/2021-03-27T14:50:31+00:00https://hemogenyx.com/announcements/cdx-antibody-update/2021-03-31T19:48:51+01:00https://hemogenyx.com/announcements/cdx-option-update/2021-04-13T22:14:07+01:00https://hemogenyx.com/announcements/conversion-of-convertible-loan-notes-3/2021-04-16T10:53:36+01:00https://hemogenyx.com/announcements/conversion-of-convertible-loan-notes-4/2021-04-25T21:10:40+01:00https://hemogenyx.com/announcements/total-voting-rights-5/2021-04-29T16:07:06+01:00https://hemogenyx.com/announcements/final-results-for-the-year-ended-31-december-2020/2021-05-04T18:49:45+01:00https://hemogenyx.com/announcements/conversion-of-convertible-loan-notes-5/2021-05-05T12:58:57+01:00https://hemogenyx.com/announcements/publication-of-supplementary-prospectus/2021-05-12T12:07:05+01:00https://hemogenyx.com/announcements/loan-notes-sale-conversion-facility-terminated/2021-05-18T15:48:52+01:00https://hemogenyx.com/announcements/director-pdmr-shareholding-9/2021-05-18T18:46:42+01:00https://hemogenyx.com/announcements/termination-of-mint-facility-admission-of-shares/2021-05-25T23:39:10+01:00https://hemogenyx.com/announcements/tr-1-standard-form-for-notification-of-major-holdings-5/2021-05-27T11:22:33+01:00https://hemogenyx.com/announcements/tr-1-standard-form-for-notification-of-major-holdings-6/2021-05-27T11:22:47+01:00https://hemogenyx.com/announcements/total-voting-rights-6/2021-05-28T09:43:57+01:00https://hemogenyx.com/announcements/posting-of-annual-report-notice-of-annual-general-meeting-2/2021-05-28T14:03:22+01:00https://hemogenyx.com/announcements/u-s-approval-and-issuance-of-cdx-antibody-patent/2021-06-02T16:12:29+01:00https://hemogenyx.com/announcements/changes-to-2021-agm-arrangements/2021-06-28T10:51:29+01:00https://hemogenyx.com/announcements/result-of-annual-general-meeting/2021-06-25T15:34:09+01:00https://hemogenyx.com/announcements/corporate-presentation/2021-07-02T11:37:30+01:00https://hemogenyx.com/announcements/appointment-of-business-advisor-board-observer/2021-07-25T20:17:32+01:00https://hemogenyx.com/announcements/u-s-approval-and-issuance-of-monoclonal-antibody-patent/2021-09-02T11:23:23+01:00https://hemogenyx.com/announcements/1348/2021-09-30T22:49:27+01:00https://hemogenyx.com/announcements/cdx-licence-agreement/2021-10-15T14:36:59+01:00https://hemogenyx.com/announcements/lease-of-new-york-mink-building-custom-laboratory/2021-10-15T19:48:46+01:00https://hemogenyx.com/announcements/convertible-loans-repayment/2021-11-24T14:39:41+00:00https://hemogenyx.com/announcements/hemo-car-t-pre-ind-meeting-request/2021-12-13T14:30:17+00:00https://hemogenyx.com/announcements/1370/2022-01-04T21:58:06+00:00https://hemogenyx.com/announcements/h-c-wainwright-bioconnect-conference/2022-01-04T22:34:10+00:00https://hemogenyx.com/announcements/hemogenyx-pharmaceuticals-partnership-with-selexis-sa-to-advance-cdx-development/2022-01-12T00:01:42+00:00https://hemogenyx.com/announcements/hemo-car-t-pre-ind-meeting-request-2/2022-02-18T00:03:28+00:00https://hemogenyx.com/announcements/1385/2022-03-17T05:13:59+00:00https://hemogenyx.com/announcements/final-results-for-the-year-ended-31-december-2021/2022-04-29T20:20:23+01:00https://hemogenyx.com/announcements/immuno-oncology-summit-europe-presentation/2022-05-15T11:10:56+01:00https://hemogenyx.com/announcements/director-pdmr-shareholding-10/2022-05-29T22:43:56+01:00https://hemogenyx.com/announcements/posting-of-annual-report-notice-of-annual-general-meeting-3/2022-06-07T14:19:19+01:00https://hemogenyx.com/announcements/investor-webinar/2022-06-24T22:24:16+01:00https://hemogenyx.com/announcements/result-of-annual-general-meeting-2/2022-06-30T15:35:56+01:00https://hemogenyx.com/announcements/change-of-registered-office/2022-07-01T12:22:05+01:00https://hemogenyx.com/announcements/investor-webinar-recording/2022-07-08T12:43:53+01:00https://hemogenyx.com/announcements/new-custom-r-d-facility-opening/2022-07-13T11:45:56+01:00https://hemogenyx.com/announcements/appointment-of-medical-director/2022-08-10T02:59:34+01:00https://hemogenyx.com/announcements/approval-and-issuance-of-chinese-bi-specific-antibody-patent/2022-08-15T11:47:34+01:00https://hemogenyx.com/announcements/appointment-of-director-of-quality/2022-08-19T12:49:12+01:00https://hemogenyx.com/announcements/presentation-at-h-c-wainwright-global-investment-conference/2022-09-01T12:46:57+01:00https://hemogenyx.com/announcements/half-year-report-interim-results-for-the-period-ended-30-june-2022/2022-09-29T10:05:06+01:00https://hemogenyx.com/announcements/1513/2022-11-18T15:20:32+00:00https://hemogenyx.com/announcements/hemo-car-t-first-process-qualification-run-completed/2022-12-13T15:21:34+00:00https://hemogenyx.com/announcements/hemo-car-t-second-process-qualification-run-completed/2023-01-03T19:50:32+00:00https://hemogenyx.com/announcements/single-cbr-can-treat-multiple-viruses/2024-04-25T01:31:27+01:00https://hemogenyx.com/announcements/hemo-car-t-third-process-qualification-run-completed/2023-03-26T23:24:03+01:00https://hemogenyx.com/announcements/placing-to-raise-4-056-250/2023-01-26T07:57:28+00:00https://hemogenyx.com/announcements/total-voting-rights-7/2023-02-27T12:44:58+00:00https://hemogenyx.com/announcements/admission-of-shares-to-official-list/2023-02-07T14:31:46+00:00https://hemogenyx.com/announcements/hemo-car-t-analytical-release-tests-completed/2023-03-26T23:24:22+01:00https://hemogenyx.com/announcements/final-results-for-the-year-ended-31-december-2022/2023-04-28T07:07:02+01:00https://hemogenyx.com/announcements/equity-incentive-plan-pool-increase-and-grant-of-share-options/2023-04-28T10:24:26+01:00https://hemogenyx.com/announcements/submission-of-ind-for-hemo-car-t/2023-05-08T22:16:29+01:00https://hemogenyx.com/announcements/posting-of-annual-report-notice-of-annual-general-meeting-4/2023-06-02T14:21:37+01:00https://hemogenyx.com/announcements/hemogenyx-pharmaceuticals-announces-clinical-hold-on-ind-for-hemo-car-t/2023-06-02T14:16:22+01:00https://hemogenyx.com/announcements/result-of-annual-general-meeting-3/2024-04-25T01:55:25+01:00https://hemogenyx.com/announcements/full-fda-review-for-hemo-car-t-ind/2023-07-10T11:43:17+01:00https://hemogenyx.com/announcements/cbr-patent-application-update/2024-04-25T02:04:31+01:00https://hemogenyx.com/announcements/clinical-hold-lift-plan-is-accepted-by-fda/2024-03-28T20:33:16+00:00https://hemogenyx.com/announcements/hemogenyx-pharmaceuticals-announces-strategic-investment-from-prevail-partners-llc/2024-03-28T20:33:59+00:00https://hemogenyx.com/announcements/half-year-report-interim-results-for-the-period-ended-30-june-2023/2024-04-25T01:39:51+01:00https://hemogenyx.com/announcements/lentivirus-re-manufacturing-completed/2024-04-25T02:36:34+01:00https://hemogenyx.com/announcements/cbr-expanded-to-treatment-of-cancer/2024-04-25T02:37:31+01:00https://hemogenyx.com/announcements/placing-to-raise-534375/2024-04-25T02:41:15+01:00https://hemogenyx.com/announcements/hemo-car-t-process-qualification-run-completed/2024-04-25T02:47:52+01:00https://hemogenyx.com/announcements/submission-of-complete-response-to-clinical-hold-for-hemo-car-t-ind/2024-04-25T02:48:59+01:00https://hemogenyx.com/announcements/approval-and-issuance-of-u-s-conditioning-patent/2024-04-25T02:49:41+01:00https://hemogenyx.com/announcements/fda-consents-to-phase-i-trials-of-hemo-car-t/2024-04-25T02:50:32+01:00https://hemogenyx.com/announcements/cbr-intranasal-delivery/2024-04-25T02:53:00+01:00https://hemogenyx.com/announcements/cbr-brain-delivery/2024-04-25T02:54:21+01:00https://hemogenyx.com/announcements/placing-to-raise-us4-2-million/2024-04-25T02:56:18+01:00https://hemogenyx.com/announcements/total-voting-rights-8/2024-04-25T02:56:58+01:00https://hemogenyx.com/announcements/total-voting-rights-9/2024-04-25T01:43:25+01:00https://hemogenyx.com/announcements/final-results/2024-04-25T04:12:15+01:00https://hemogenyx.com/announcements/posting-of-annual-report-and-notice-of-annual-general-meeting/2024-06-27T11:32:58+01:00https://hemogenyx.com/announcements/operations-update/2024-06-27T12:06:55+01:00https://hemogenyx.com/announcements/result-of-annual-general-meeting-4/2024-06-27T16:26:02+01:00https://hemogenyx.com/announcements/presentation-at-macrophage-directed-therapies-summit/2024-08-28T12:31:59+01:00https://hemogenyx.com/announcements/presentation-at-cbd-st-conference/2024-08-28T17:53:13+01:00https://hemogenyx.com/announcements/cdx-development-update/2024-09-02T22:13:51+01:00https://hemogenyx.com/announcements/flt3-assay-ready-for-phase-i-trials-at-md-anderson/2024-09-12T16:21:35+01:00https://hemogenyx.com/announcements/half-year-report-interim-results-for-the-period-ended-30-june-2024/2024-09-27T15:26:44+01:00https://hemogenyx.com/announcements/strategic-investment-from-prevail-partners-llc/2024-10-06T16:48:49+01:00https://hemogenyx.com/announcements/schedule-for-phase-i-clinical-trial-opening/2024-11-01T17:02:25+00:00https://hemogenyx.com/announcements/institutional-investment-of-600000/2024-11-12T17:43:53+00:00https://hemogenyx.com/announcements/irb-approval-for-phase-i-clinical-trial/2024-11-26T17:09:20+00:00https://hemogenyx.com/announcements/notice-of-extraordinary-general-meeting/2024-11-26T17:40:41+00:00https://hemogenyx.com/announcements/total-voting-rights-10/2024-11-29T12:28:39+00:00https://hemogenyx.com/announcements/cbr-macrophage-delivery/2024-12-10T01:04:25+00:00https://hemogenyx.com/announcements/site-initiation-visit-completed/2024-12-10T01:11:03+00:00https://hemogenyx.com/announcements/result-of-extraordinary-general-meeting/2024-12-10T01:15:12+00:00https://hemogenyx.com/announcements/capital-re-organisation-and-new-isin/2024-12-19T15:50:09+00:00https://hemogenyx.com/announcements/ultrafast-car-t-manufacturing/2024-12-19T18:30:05+00:00https://hemogenyx.com/announcements/opening-of-first-clinical-site/2025-01-06T10:59:09+00:00https://hemogenyx.com/announcements/total-voting-rights-11/2025-01-06T11:14:36+00:00https://hemogenyx.com/announcements/change-of-company-secretary-and-registered-office/2025-01-06T12:35:16+00:00https://hemogenyx.com/announcements/placing-to-raise-340000/2025-01-27T12:01:26+00:00https://hemogenyx.com/announcements/total-voting-rights-12/2025-02-23T20:18:30+00:00https://hemogenyx.com/announcements/issue-of-convertible-loan-notes-to-raise-285000/2025-02-23T20:30:53+00:00https://hemogenyx.com/announcements/first-in-human-treatment-with-hg-ct-1-for-relapsed-or-refractory-acute-myeloid-leukemia/2025-02-24T09:06:43+00:00https://hemogenyx.com/announcements/conversion-of-convertible-loan-notes-and-admission-of-shares/2025-04-16T15:11:56+01:00https://hemogenyx.com/announcements/recruitment-of-second-patient-for-hg-ct-1-clinical-trial/2025-04-16T17:54:22+01:00https://hemogenyx.com/announcements/first-patient-initial-safety-tests/2025-04-23T01:42:19+01:00https://hemogenyx.com/announcements/institutional-backing-of-709200-for-continuing-phase-1-clinical-trials/2025-04-23T01:49:24+01:00https://hemogenyx.com/announcements/total-voting-rights-13/2025-06-02T10:15:18+01:00https://hemogenyx.com/announcements/hemogenyx-pharmaceuticals-files-annual-ind-report-with-fda-for-hg-ct-1-car-t-therapy-for-aml/2025-04-23T01:59:18+01:00https://hemogenyx.com/announcements/final-results-2/2025-04-29T01:53:47+01:00https://hemogenyx.com/announcements/second-patient-treated-with-hg-ct-1-car-t-therapy/2025-06-01T20:37:34+01:00https://hemogenyx.com/announcements/posting-of-annual-report-notice-of-annual-general-meeting-5/2025-06-01T22:34:17+01:00https://hemogenyx.com/announcements/placing-to-raise-451250-and-directors-dealing/2025-06-01T22:49:47+01:00https://hemogenyx.com/announcements/agm-correction/2025-06-01T23:00:16+01:00https://hemogenyx.com/announcements/pediatric-amendment-to-clinical-protocol/2025-06-01T23:06:31+01:00https://hemogenyx.com/announcements/result-of-agm-2/2025-06-01T23:29:49+01:00https://hemogenyx.com/announcements/20250530-total-voting-rights/2025-06-01T23:37:36+01:00https://hemogenyx.com/announcements/second-patient-passes-initial-safety-tests/2025-06-04T03:52:13+01:00https://hemogenyx.com/announcements/placing-to-raise-451250-and-directors-dealing-2/2025-06-04T04:24:20+01:00https://hemogenyx.com/announcements/clearance-to-proceed-with-pediatric-expansion/2025-06-20T20:26:33+01:00https://hemogenyx.com/announcements/total-voting-rights-14/2025-06-30T11:16:24+01:00https://hemogenyx.com/announcements/hemogenyx-awarded-grant/2025-07-20T18:34:49+01:00https://hemogenyx.com/announcements/placing-to-raise-250000-and-directors-dealing/2025-07-29T22:34:50+01:00https://hemogenyx.com/announcements/total-voting-rights-15/2025-07-29T22:56:54+01:00https://hemogenyx.com/announcements/publication-of-prospectus-2/2025-11-19T18:08:45+00:00https://hemogenyx.com/announcements/third-patient-treated-with-hg-ct-1-car-t-therapy/2025-11-19T22:59:26+00:00https://hemogenyx.com/announcements/hemogenyx-secures-570000-to-continue-its-phase-1-clinical-trials-and-directors-dealing/2025-11-19T23:08:28+00:00https://hemogenyx.com/announcements/result-of-audit-tender/2025-11-19T23:24:33+00:00https://hemogenyx.com/announcements/issue-of-convertible-loan-notes-to-raise-620000/2025-11-19T23:30:52+00:00https://hemogenyx.com/announcements/exercise-of-warrants-and-issue-of-equity/2025-11-20T00:59:11+00:00https://hemogenyx.com/announcements/exercise-of-warrants-and-issue-of-equity-2/2025-11-20T01:01:00+00:00https://hemogenyx.com/announcements/manufacturing-partnership-with-made-scientific/2025-11-20T01:11:31+00:00https://hemogenyx.com/announcements/invitation-to-participate-at-dcny-summit/2025-11-20T01:15:17+00:00https://hemogenyx.com/announcements/third-patient-safety-evaluation/2025-11-20T01:24:03+00:00https://hemogenyx.com/announcements/holdings-in-company/2025-11-20T01:36:20+00:00https://hemogenyx.com/announcements/letter-of-intent-with-cellin-technologies/2025-11-20T01:50:13+00:00https://hemogenyx.com/announcements/total-voting-rights-16/2025-11-20T01:54:34+00:00https://hemogenyx.com/announcements/half-year-report/2026-09-28T18:37:08+01:00https://hemogenyx.com/announcements/clearance-to-initiate-pediatric-enrolment/2025-11-20T02:15:44+00:00https://hemogenyx.com/announcements/clinical-trial-update-and-grant-of-share-awards/2025-11-20T02:22:18+00:00https://hemogenyx.com/announcements/total-voting-rights-20251128/2025-12-01T13:17:15+00:00https://hemogenyx.com/announcements/holdings-in-company-2/2025-12-08T20:39:36+00:00https://hemogenyx.com/announcements/issue-of-equity/2025-12-18T12:33:35+00:00https://hemogenyx.com/announcements/update-on-admission-of-shares/2026-08-17T00:24:44+01:00https://hemogenyx.com/announcements/holdings-in-company-3/2026-09-01T23:14:29+01:00https://hemogenyx.com/announcements/total-voting-rights-17/2026-09-01T23:17:57+01:00https://hemogenyx.com/announcements/hemogenyx-secures-2500000-to-continue-its-phase-1-clinical-trials/2026-09-01T23:27:52+01:00https://hemogenyx.com/announcements/hemogenyx-secures-2500000-to-continue-its-phase-1-clinical-trials-correction/2026-09-01T23:30:11+01:00https://hemogenyx.com/announcements/exercise-of-warrants-and-issue-of-equity-3/2026-09-01T23:34:12+01:00https://hemogenyx.com/announcements/holdings-in-company-4/2026-09-01T23:54:24+01:00https://hemogenyx.com/announcements/tech-transfer-completion-and-clinical-trial-progress/2026-09-02T00:04:28+01:00https://hemogenyx.com/announcements/total-voting-rights-18/2026-09-01T23:58:07+01:00https://hemogenyx.com/announcements/institutional-fundraise/2026-09-02T00:24:07+01:00https://hemogenyx.com/announcements/filing-of-annual-ind-report-with-fda/2026-09-02T00:29:37+01:00https://hemogenyx.com/announcements/final-results-3/2026-09-03T23:02:15+01:00https://hemogenyx.com/announcements/grant-of-options-and-extension-of-warrant-term/2026-09-02T01:43:59+01:00https://hemogenyx.com/announcements/notice-of-agm-2/2026-09-02T01:59:13+01:00https://hemogenyx.com/announcements/result-of-agm-3/2026-09-02T02:06:50+01:00https://hemogenyx.com/announcements/collaboration-and-company-update/2026-09-02T02:16:11+01:00https://hemogenyx.com/announcements/collaboration-with-cellin-technologies/2026-09-02T02:24:47+01:00https://hemogenyx.com/announcements/exercise-of-warrants-and-issue-of-equity-4/2026-09-03T23:07:05+01:00https://hemogenyx.com/announcements/half-year-report-interim-results-for-the-period-ended-30-june-2026/2026-09-28T18:43:26+01:00